Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives $35.22 Average Price Target from Brokerages

Definium Therapeutics, Inc. (NASDAQ:DFTX) has earned an average recommendation of “Buy” from the twelve brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $35.2222.

DFTX has been the topic of a number of recent research reports. Jefferies Financial Group assumed coverage on shares of Definium Therapeutics in a research note on Thursday, January 29th. They issued a “buy” rating and a $30.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Definium Therapeutics in a research report on Monday, February 2nd. Royal Bank Of Canada lifted their price target on Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Needham & Company LLC reissued a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Finally, Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th.

Insider Buying and Selling at Definium Therapeutics

In other Definium Therapeutics news, insider Mark Sullivan sold 11,276 shares of the firm’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the transaction, the insider directly owned 282,576 shares in the company, valued at approximately $3,715,874.40. This trade represents a 3.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel Karlin sold 5,600 shares of the stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $73,640.00. Following the completion of the sale, the insider owned 425,025 shares of the company’s stock, valued at approximately $5,589,078.75. This represents a 1.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 42,667 shares of company stock worth $561,071. Corporate insiders own 2.26% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DFTX. Marshall Wace LLP increased its position in shares of Definium Therapeutics by 31.9% during the second quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock valued at $22,204,000 after acquiring an additional 828,067 shares during the last quarter. Commodore Capital LP increased its position in shares of Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after purchasing an additional 475,000 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Definium Therapeutics during the 3rd quarter valued at $4,337,000. Rosalind Advisors Inc. raised its stake in shares of Definium Therapeutics by 78.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after purchasing an additional 330,000 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in shares of Definium Therapeutics by 424.9% in the 3rd quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock worth $3,495,000 after buying an additional 239,965 shares during the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Price Performance

Shares of DFTX opened at $17.38 on Friday. Definium Therapeutics has a 12-month low of $4.70 and a 12-month high of $18.70. The business’s fifty day moving average is $14.98 and its 200 day moving average is $12.46. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31. The stock has a market cap of $1.71 billion, a P/E ratio of -8.52 and a beta of 2.57.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.